KRM Ayurveda H1 profit more than doubles as margins expand
Key highlights
- KRM Ayurveda’s H1 FY27 total income rose 40.10% to Rs 68.17 crore.
- KRM Ayurveda’s H1 FY27 PAT rose 109.55% to Rs 17.23 crore.
- KRM Ayurveda’s H1 FY27 PAT margin expanded 837.80 basis points to 25.28%.
- Services accounted for 62.63% of KRM Ayurveda’s H1 FY27 sales of products and services.
powered by IRIS

KRM Ayurved Limited, referred to as KRM Ayurveda, reported H1 FY27 consolidated net profit of Rs 17.23 crore, up 109.55% year on year, as its PAT margin reached 25.28% from 16.90%. Total income rose 40.10% to Rs 68.17 crore, while EBITDA increased 79.81% to Rs 23.82 crore.
Know KRM Ayurveda inside out
Results, valuation, peers and who's buying, in one view.
How did KRM Ayurveda’s H1 FY27 earnings change?
KRM Ayurveda grew total income by 40.10% to Rs 68.17 crore in H1 FY27, while earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 79.81% to Rs 23.82 crore and profit after tax, or PAT, increased 109.55% to Rs 17.23 crore. In H1 FY26, total income was Rs 48.65 crore, EBITDA was Rs 13.25 crore and PAT was Rs 8.22 crore.
KRM Ayurveda’s PAT rose faster than both total income and EBITDA during the six months. PAT growth was 69.45 percentage points above total-income growth, while EBITDA growth was 39.71 percentage points above income growth, based on the reported H1 FY27 comparisons.
Earnings per share, or EPS, rose 52.83% to Rs 8.10 in H1 FY27 from Rs 5.30 in H1 FY26. The increase in EPS was below the 109.55% rise in PAT, while the presentation does not provide a share-count bridge or another explanation for the difference.
Management said the H1 FY27 result reflected its focus on profitable growth and operational efficiency. Its commentary rounded total income to Rs 68.17 crore and cited EBITDA growth of 79.81% and PAT growth of 109.55%, but the presentation does not provide a line-by-line cost analysis for the increase in profitability.
What changed in KRM Ayurveda’s profitability margins?
KRM Ayurveda’s EBITDA margin increased to 34.95% in H1 FY27 from 27.23% in H1 FY26, while PAT margin rose to 25.28% from 16.90%. The company reported margin expansion of 771.92 basis points for EBITDA and 837.80 basis points for PAT; one basis point equals one-hundredth of a percentage point.
The margin movement coincided with EBITDA growing by Rs 10.57 crore, from Rs 13.25 crore to Rs 23.82 crore, and PAT increasing by Rs 9.01 crore, from Rs 8.22 crore to Rs 17.23 crore. Total income increased by Rs 19.51 crore over the same H1 FY26 comparison period.
The difference between EBITDA margin and PAT margin narrowed to 9.67 percentage points in H1 FY27 from 10.33 percentage points in H1 FY26. That calculation uses the reported EBITDA and PAT margins of 34.95% and 25.28% in H1 FY27, compared with 27.23% and 16.90% a year earlier.
Management attributed the H1 FY27 margin expansion to improved profitability and operational efficiency. KRM Ayurveda did not disclose a future EBITDA-margin or PAT-margin target in the presentation, so the supplied material establishes the reported half-year change rather than a forecast for later periods.
Got a follow-up? Ask IRIS
How did KRM Ayurveda’s Q2 FY27 compare with H1?
KRM Ayurveda reported Q2 FY27 total income of Rs 35.30 crore, EBITDA of Rs 11.26 crore and PAT of Rs 8.15 crore. Against Q2 FY26, income rose 48.08% from Rs 23.84 crore, EBITDA rose 63.60% from Rs 6.88 crore and PAT rose 95.37% from Rs 4.17 crore.
Q2 FY27 EBITDA margin was 31.91%, compared with 28.88% in Q2 FY26, an increase of 302.62 basis points. PAT margin reached 23.08%, up 558.57 basis points from 17.49%, while EPS rose 42.38% to Rs 3.83 from Rs 2.69.
H1 FY27 margins exceeded the reported Q2 FY27 levels, with EBITDA margin at 34.95% for H1 versus 31.91% for Q2 and PAT margin at 25.28% versus 23.08%. The presentation reports the quarterly and half-year figures but does not explain why the H1 margins were higher than the Q2 levels.
How has KRM Ayurveda’s products and services mix changed?
KRM Ayurveda derived 62.63% of H1 FY27 sales of products and services from services and 37.37% from products. The company reported service sales of Rs 41.95 crore and product sales of Rs 25.03 crore, producing a stated total of Rs 66.98 crore for that revenue classification.
The services share increased from 53.77% in FY26 and 35.70% in FY25, while the products share declined from 46.23% and 64.30%, respectively. The longer comparison is more pronounced against FY24, when products represented 90.30% of sales of products and services and services represented 9.70%.
The Rs 66.98 crore sales-of-products-and-services total for H1 FY27 was Rs 1.19 crore below the Rs 68.17 crore consolidated total income reported in the financial scorecard. The presentation labels the two measures differently and does not disclose a reconciliation between sales of products and services and total income.
Management said it is building an integrated Ayurvedic healthcare platform spanning hospitals, day-care centres, clinical expertise and wellness products. As of 30 September 2026, KRM Ayurveda reported 8 hospitals, 10 day-care centres, 326 beds, 60% bed occupancy and 5 service segments.
Conclusion
KRM Ayurveda’s H1 FY27 results showed profit growth outpacing income growth: total income increased 40.10%, EBITDA rose 79.81% and PAT climbed 109.55%. The reported expansion of EBITDA margin to 34.95% and PAT margin to 25.28%, alongside services accounting for 62.63% of H1 product-and-service sales, marked the central changes in the period.
The next disclosed developments are management’s additional 80-bed hospital in Gurugram, its expanding presence in Pitampura, Janakpuri and Vashi, and the acquisition of Karma Nutravedics for entry into nutraceuticals and wellness. The presentation reports 5 National Accreditation Board for Hospitals and Healthcare Providers, or NABH, accredited Panchakarma centres, but gives no opening timetable for the Gurugram facility, acquisition financial targets or future margin guidance.


